THOROFARE, NJ–(Mar 28, 2017) – Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the “Company” or “Akers Bio”), a developer of rapid health information technologies, has received an initial order for the Company’s rapid cholesterol self-test from First Check Diagnostics, LLC (“First Check”), the exclusive distributor for this product in the United States, for sale under their popular “First Check” brand.

First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo.

Akers Bio’s Tri-Cholesterol “Check” test is the only combined rapid test which provides an estimate of a person’s Total cholesterol as well as their High Density Lipoprotein (“HDL”) cholesterol levels – their ‘good cholesterol’; thereby providing an estimate of a person’s Low Density Lipoprotein (“LDL”) levels – their ‘bad cholesterol’. These features are essential to accurately differentiating between a person’s ‘good’ and ‘bad’ cholesterol thereby making it a truly effective screening test for high cholesterol.

The Tri-Cholesterol “Check” test is disposable, uses just a finger-stick blood sample and gives a result in only 5 minutes. The test has FDA 510(k) clearance in the United States; as well as a CE mark for the European Economic Area.

According to the United States Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the United States have high ‘bad cholesterol’ and less than 1 in every 3 of them has the condition under control. Too much cholesterol puts people at risk for heart disease and stroke, two leading causes of death in the United States. However, with responsible actions such as self-testing with Akers Bio’s Tri-Cholesterol “Check” test, people can take steps to manage their cholesterol levels and lower their risk.

John J. Gormally, Chief Executive Officer of Akers Bio, commented: “I am delighted that we will soon have this over-the-counter health and wellness product from Akers Bio on the shelves of major US retailers under the distinguished First Check brand. It is a great endorsement of our rapid testing technology. We look forward to building this revenue stream with our distribution partner and providing people in America with a fast, convenient and meaningful way to evaluate and manage their cholesterol, which is a serious concern for millions of people.”

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698

finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500

Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com